Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls.
Pancreatic adenocarcinoma (PaC) is one of most difficult tumors to treat. Much of this is attributed to the late diagnosis. To identify biomarkers for early detection, we examined DNA methylation differences in leukocyte DNA between PaC cases and controls in a two-phase study. In phase I, we measure...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-03-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3063802?pdf=render |